Benitec Biopharma Inc.

AI-generated fair value estimate for this company.

Method: Risk-adjusted NPV (rNPV) of pipeline plus net cash: $400M combined assumed peak annual sales across the BB-301 (OPMD gene therapy) lead program and earlier pipeline; 3x peak-sales NPV multiple; 15% probability of success (later-stage, Phase 1b/2 orphan-disease program); discounted 5 years to launch at a 12% rate; plus $179.21M current net cash; 34.88M shares outstanding.

Reasoning: Benitec is a clinical-stage gene-therapy biotech with no product revenue but a large cash balance relative to its market cap, so intrinsic value is driven by net cash plus a probability-weighted NPV of its rare-disease pipeline; the higher probability of success versus an earlier-stage biotech reflects BB-301's more advanced Phase 1b/2 status in a well-defined orphan indication.